ClinicalTrials.gg
TerminatedNCT03870763Updated Jun 15, 2023Results posted

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

A Phase 3 interventional study of Dimethyl Fumarate and Peginterferon Beta-1a in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Terminated at 23 sites in 13 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Why this study was terminated
Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
17th of 22
11 · median 61
Started
2019
the only one that year
Phase 3
10 of 22
none open now
Registered
22nd of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 17th largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 22nd registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS. The other objectives of this study are to evaluate the safety and tolerability of dimethyl fumarate and peginterferon beta-1a and to assess the effect of dimethyl fumarate and peginterferon beta-1a, both compared with placebo, on additional clinical and radiological measures of disease activity.

Read the detailed description

Participants will be randomized in a 1:2:2 ratio to receive the double-blind study treatment (Dimethyl Fumarate, Peginterferon Beta-1a, and placebo). Participants experiencing a confirmed relapse or disability progression or high lesion burden on MRI will have the option to discontinue the blinded study treatment and switch to an alternative therapy or open-label BG00012.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Pediatric, Multiple Sclerosis
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have a diagnosis of RRMS as defined by the revised consensus definition for pediatric MS
  • Must have an EDSS score between 0.0 and 5.0.
  • Must have a body weight of ≥30 kg
  • Must have experienced ≥1 relapse in the 12 months prior to randomization (Day 1), or must have evidence of asymptomatic disease activity seen on MRI in the 6 months prior to randomization, or ≥2 relapses in the 24 months prior to randomization (Day 1). Relapse is defined as the occurrence of a clinical demyelination event regardless of whether the event is a first or subsequent demyelinating event.

Key Exclusion Criteria:

  • Participants having primary progressive, secondary progressive, or progressive RMS.
  • Disorders mimicking MS, such as other demyelinating disorders, systemic disorders, metabolic disorders, and infectious disorders.
  • History of cardiovascular, pulmonary, GI, hepatic, renal, endocrinologic, hematologic, immunologic, metabolic, dermatologic, growth, developmental, psychiatric (including depression), neurologic (other than MS), and/or other major disease and/or laboratory abnormality indicative thereof, that would preclude participation in a clinical study
  • Occurrence of an MS relapse within the 30 days prior to randomization (Day 1) and/or the subject has not stabilized from a previous relapse prior to randomization

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Dimethyl Fumarate 240 mg

    Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).

    Drug: Dimethyl Fumarate

  • Experimental
    Peginterferon Beta-1a 125 µg

    Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).

    Drug: Peginterferon Beta-1a

  • Placebo comparator
    Placebo

    Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)

    Drug: Placebo

Interventions

  • Administered as specified in the treatment arm.

    Also known as: Tecfidera, BG00012

  • Administered as specified in the treatment arm.

    Also known as: Plegridy, BIIB017

  • DrugPlacebo

    Administered as specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. Time to First Relapse

    A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. Time to relapse is defined as from the first dose of the study drug to the day of relapse. Time to First Relapse is estimated by Kaplan Mayer method.

    Time frame: Baseline up to Week 96

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to Week 100

  2. Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 48 and 96

    The number of new or newly enlarging T2 hyperintense lesions that developed in each participant assessed on magnetic resonance imaging (MRI) scans.

    Time frame: Weeks 48 and 96

  3. Number of Galdolinium (Gd)-Enhancing Lesions at Weeks 48 and 96

    The number of Gd-enhancing lesions was assessed by using MRI scans.

    Time frame: Weeks 48 and 96

  4. Annualized Relapse Rate

    A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. The relapse rate for an individual participant was calculated as the number of relapses for that participant divided by the number of participant-years followed. The ARR for each enrolment group was calculated as the total number of relapses experienced in the group divided by the total number of participant-years on the study. An unadjusted relapse rate is reported.

    Time frame: Up to Week 96

07

Results

Posted May 16, 2023
Limitations and caveats
The study was terminated because of long-term difficulties in fulfilling the enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials. Decision to stop study was not based on safety concerns.

Participant flow

Participants were enrolled at the investigative sites in Estonia, Tunisia, Turkey, Jordan and Taiwan from 19 March 2019 to 21 July 2022.

Participant flow — Overall Study
MilestoneDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
Started263
Completed232
Not completed031
Withdrew: Study terminated by sponsor020
Withdrew: Withdrawal by subject010
Withdrew: Worsening of multiple sclerosis attack001

Outcome measures

PrimaryTime to First Relapse

A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. Time to relapse is defined as from the first dose of the study drug to the day of relapse. Time to First Relapse is estimated by Kaplan Mayer method.

Time frame:
Baseline up to Week 96
Reported as:
Median · Days
Time to First Relapse
DaysDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
Time to First Relapse413 (413 to 413)NA (NA to NA)166.5 (113 to 220)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Baseline up to Week 100
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
AEs263
SAEs101
SecondaryNumber of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 48 and 96

The number of new or newly enlarging T2 hyperintense lesions that developed in each participant assessed on magnetic resonance imaging (MRI) scans.

Time frame:
Weeks 48 and 96
Reported as:
Mean · number of lesions
Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 48 and 96
number of lesionsDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
Week 480.5 (0 to 1)1.0 (0 to 3)3.3 (2 to 4)
Week 962.5 (0 to 5)1.3 (0 to 3)3.5 (2 to 5)
SecondaryNumber of Galdolinium (Gd)-Enhancing Lesions at Weeks 48 and 96

The number of Gd-enhancing lesions was assessed by using MRI scans.

Time frame:
Weeks 48 and 96
Reported as:
Mean · number of lesions
Number of Galdolinium (Gd)-Enhancing Lesions at Weeks 48 and 96
number of lesionsDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
Week 480 (0 to 0)0 (0 to 0)1.5 (0 to 3)
Week 960 (0 to 0)0.25 (0 to 1)0.5 (0 to 1)
SecondaryAnnualized Relapse Rate

A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. The relapse rate for an individual participant was calculated as the number of relapses for that participant divided by the number of participant-years followed. The ARR for each enrolment group was calculated as the total number of relapses experienced in the group divided by the total number of participant-years on the study. An unadjusted relapse rate is reported.

Time frame:
Up to Week 96
Reported as:
Number · relapses per participant year
Annualized Relapse Rate
relapses per participant yearDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
Annualized Relapse Rate0.260.000.46

Adverse events

Collected over Baseline up to Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dimethyl Fumarate 240 mg0/2 (0%)1/2 (50%)2/2 (100%)
Peginterferon Beta-1a 125 µg0/6 (0%)0/6 (0%)6/6 (100%)
Placebo0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
Multiple sclerosis relapseNervous system disorders1/20/61/3
Most frequent other events
Showing 10 of 37
Most frequent other events
EventDimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlacebo
HeadacheNervous system disorders1/24/61/3
Multiple sclerosis relapseNervous system disorders1/20/62/3
Vaginal infectionInfections and infestations1/20/60/3
CoughRespiratory, thoracic and mediastinal disorders1/20/60/3
ErythemaSkin and subcutaneous tissue disorders1/20/60/3
Iron deficiency anaemiaBlood and lymphatic system disorders0/20/61/3
Abdominal painGastrointestinal disorders0/22/60/3
DiarrhoeaGastrointestinal disorders0/20/61/3
Gastrointestinal disorderGastrointestinal disorders0/20/61/3
FatigueGeneral disorders0/21/61/3

Baseline characteristics

Safety population included all participants who had received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Dimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlaceboTotal
Mean15.5 ± 2.1215.7 ± 1.5115.7 ± 1.1515.6 ± 1.36
Sex: Female, Male
Sex: Female, Male(Participants)Dimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlaceboTotal
Female1528
Male1113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino26311
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dimethyl Fumarate 240 mgPeginterferon Beta-1a 125 µgPlaceboTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White25310
More than one race0000
Unknown or Not Reported0000
08

Study locations

23 sites
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Medellín, Colombia
  • Research Site
    Tallinn, 11315, Estonia
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Ar-Ramtha, Jordan
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Petaling Jaya, Malaysia
  • Research Site
    Seberang Jaya, Malaysia
  • Research Site
    Guadalajara, Mexico
  • Research Site
    Morelia, Mexico
  • Research Site
    Santa Cruz, Mexico
  • Research Site
    Dammam, Saudi Arabia
  • Research Site
    Riyadh, Saudi Arabia
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Bangkok, Thailand
  • Research Site
    Manouba, Tunisia
  • Research Site
    Monastir, Tunisia
  • Research Site
    Sfax, Tunisia
  • Research Site
    Tunis, Tunisia
  • Research Site
    Ankara, Turkey
  • Research Site
    Izmir, Turkey
  • Research Site
    Samsun, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jul 2022, 40 months.

Results were first posted in May 2023, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2019
First posted
Mar 12, 2019
StartActual
Mar 19, 2019
Primary completionActual
Jul 21, 2022
CompletionActual
Jul 21, 2022
Results first posted
May 16, 2023
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03870763
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 12, 2019
Start date
Mar 19, 2019
Primary completion
Jul 21, 2022
Completion
Jul 21, 2022
Results posted
May 16, 2023
Last update
Jun 15, 2023

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dimethyl Fumarate · Peginterferon beta-1a

Start the discussion